Literature DB >> 29562802

House dust mite sublingual immunotherapy in allergic rhinitis.

Sung-Woo Cho1, Doo Hee Han2, Jeong-Whun Kim1, Dong-Young Kim2, Chae-Seo Rhee1,3,4.   

Abstract

Allergen immunotherapy has been shown to be effective in treatment of allergic rhinitis (AR). Sublingual immunotherapy (SLIT) is generally recommended for treating seasonal AR in adults and children; however, questions remain in regard to AR treatment in relation to house dust mite (HDM). Due to heterogeneous formulations, different outcome reporting systems, and the lack of a standardized dose, HDM SLITs have not been standardized in published studies. Nevertheless, studies continuously report positive effects of HDM SLIT in AR, and HDM SLIT remains a treatment option for patients with HDM-induced allergic asthma that frequently co-exists with AR. Therefore, it is likely that HDM SLIT usage will increase. This review will focus on HDM SLIT in AR exclusively.

Entities:  

Keywords:  allergic rhinitis; house dust mite; sublingual immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 29562802     DOI: 10.2217/imt-2018-0013

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  2 in total

1.  Effects of Local Nasal Immunotherapy with FIP-fve Peptide and Denatured Tyrophagus putrescentiae for Storage Mite-Induced Airway Inflammation.

Authors:  Chung-Yang Yen; Ching-Hsiang Yu; Jaw-Ji Tsai; Hsiang-Kuang Tseng; En-Chih Liao
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-01-31       Impact factor: 4.291

2.  Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis.

Authors:  Thomas Proctor; Elodie Morrough; Otto Fenske; Sarah Allatt; Stephen M Hughes; Vibha Sharma; Peter D Arkwright
Journal:  Clin Transl Allergy       Date:  2020-04-20       Impact factor: 5.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.